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Osteogenesis imperfecta (OI) is a hereditary bone disorder caused by defects of type I 
collagen. Although up to 90% of patients harbor pathogenic variants in the COL1A1/2 
gene, which codes for collagen α1/2 chains, the spectrum of OI genotypes may differ 
between populations, and there is academic controversy around OI genotype-phenotype 
correlations. In the current study, 94 Ukrainian OI families were interviewed. Clinical and 
genealogical information was collected from patients in spoken form, and their phenotypes 
were described. To identify the spectrum of collagen I pathogenic variants, COL1A1/2 
mutational analysis with Sanger sequencing was performed on the youngest affected 
individual of every family. Of the 143 patients investigated, 67 (46.85%) had type I OI, 
24 (16.78%) had type III, 49 (34.27%) had type IV, and III (2.10%) had type V. The mean 
number of fractures suffered per patient per year was 1.32 ± 2.88 (type I 0.50 ± 0.43; 
type III 3.51 ± 6.18; type IV 1.44 ± 1.77; and type 5 0.77 ± 0.23). 87.23% of patients had 
skeletal deformations of different severity. Blue sclera, dentinogenesis imperfecta, and 
hearing loss were present in 87%, 55%, and 22% of patients, respectively. COL1A1/2 
pathogenic variants were harbored by 60 patients (63.83%). 27 pathogenic variants 
are described herein for the first time. The majority of the pathogenic variants were 
located in the COL1A1 gene (76.19%). Half (49.21%) of the pathogenic variants were 
represented by structural variants. OI phenotype severity was highly correlated with type 
of collagen I defect. The current article presents an analysis of the clinical manifestations 
and COL1A1/2 mutational spectrum of 94 Ukrainian OI families with 27 novel COL1A1/2 
pathogenic variants. It is hoped that this data and its analysis will contribute toward the 
increased understanding of the phenotype development and genetics of the disorder.
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INTRODUCTION
Osteogenesis imperfecta (OI) is a group of rare congenital 
disorders of the connective tissue, also known as a brittle bone 
disease. Up to 90% of OI is caused by collagen type I structural 
(i.e. qualitative) or haploinsufficiency (i.e. quantitative) defects 
(Shapiro, 2014). OI patients suffer from low bone mass, which 
results in pathological fractures and skeletal deformities. 
According to the severity of a collagen defect, patients typically 
develop bowing of long bones, rib cage deformations, scoliosis 
and kyphosis, triangular shape of the head, and short stature. 
Being the most abundant structural protein in the body, collagen 
type I is also altered in other tissues, causing dentinogenesis 
imperfecta (DI), blue sclera, muscle weakness, ligamentous 
laxity, easy bruising, cardiac valve and pulmonary abnormalities, 
and conductive or sensory hearing loss (Marini et al., 2007; 
Marini et al., 2017).
OI is one of the most common skeletal dysplasias among 
orphan diseases. Its prevalence is estimated to be 1/20,000, 
although this may be affected by OI type and diagnostic practice, 
as many mild OI cases remain underdiagnosed (Byers and Steiner, 
1992). OI phenotypes range from mild osteopenia to severe 
perinatal lethal forms (Kocher and Shapiro; Roughley et al., 2003; 
Sillence et al., 1979). The clinical classification distinguishes five 
main OI types (Sillence et al., 1979). The four classical Sillence OI 
types are: type I (mild non-deforming OI with blue sclera); type 
II (perinatal lethal); type III (severe progressive deforming); and 
type IV (moderate varied OI). Type V OI involves the ossification 
of interosseous membranes (Glorieux et al., 2000; Amor et al., 
2011; Cho et al., 2012; Semler et al., 2012).
Regardless of the various genetic causes of the remaining 
10% of OI cases, their clinical manifestations usually coincide 
with the phenotypes of individuals with COL1A1/2 pathogenic 
variants. These OI forms are autosomal recessive and arise due 
to homozygous pathogenic variants in the genes, which alter 
collagen transport, folding, post-translational modification, bone 
mineralization, and cell signaling and bone cell function (Marini 
et al., 2017). However interconnections between OI phenotype 
and genotype exist to a certain extent, many carriers of the 
same mutations might develop different phenotypes and the 
factors influencing additional phenotype modification remain 
unidentified (Marini et al., 2007).
Interviews were conducted with 94 Ukrainian OI families in 
order to gather genealogical information and clinical history and 
to describe the phenotypes of affected individuals. A COL1A1/2 
mutational analysis of the youngest affected member of each 
family was performed, to reveal the spectrum of collagen type I 
pathogenic variants in the Ukrainian OI population. Afterwards, 
genotype-phenotype correlations in the Ukrainian OI cohort 
were examined.
This current study presents for the first time the clinical 
and molecular characteristics of the Ukrainian OI population. 
Ukrainian OI population enriches pool of known COL1A1/2 
pathogenic variants with 27 novel pathogenic variants. We 
suppose that this data may advance the understanding of the 
OI genetic epidemiology; broaden current knowledge about 
the spectrum of COL1A1/2 pathogenic variants, patient’s 
phenotypes, and clinical manifestations; and help to estimate the 
scope of genotype-phenotype correlations.
SUBJECTS AND METHODS
Medical interviews were conducted with 143 individuals affected 
with OI, from 94 Ukrainian families. Patients were classified 
according to the updated Sillence OI classification types I–V 
(Warman et al., 2011). Clinical history collected by reviewing 
available medical documents and by patients declared medical 
history. Clinical examination and phenotypes description was 
done by UT medical team. Phenotypes were described on the 
basis of observation and available clinical documentation. 
Mutational analysis of the COL1A1/2 genes was conducted with 
Sanger sequencing, in order to reveal the COL1A1/2 mutational 
spectrum. OI skeletal and extraskeletal manifestations were 
compared with pathogenic variant type, to determine genotype-
phenotype correlations.
The current study was conducted in accordance with the 
Helsinki Declaration and received approval from the Sytenko 
Institute of Spine and Joint Pathology of the Ukrainian Academy 
of Medical Sciences and the Ethical Review Committee on 
Human Research of the University of Tartu (permit no. 221/
M- 34). Informed written consent from the patients or their legal 
representatives was obtained prior to inclusion in the study.
Subjects
Ukrainian OI families from the Ukrainian Association of Crystal 
People participated in the study. In May 2016 and September 
2017, Ukrainian OI patients and their relatives (from all regions 
of Ukraine) attended an interview and clinical examination with 
researchers from the University of Tartu, Estonia, in cooperation 
with Ukrainian medical staff. Patients with other skeletal disorders 
were excluded from the study during screening (five families).
A total number of 143 unrelated OI patients (66 males and 
77 females; aged from 2 months to 65 years) from 94 unrelated 
families were included in the study. Mutational analysis of the 
COL1A1/2 genes was performed on the youngest affected 
member of every OI kindred included in the study (n = 94).
Clinical Characteristics and Genealogical 
Description
In order to characterize clinical OI manifestations, patients 
underwent both clinical and physical examinations. Cases were 
classified as OI types I–V, according to the observed clinical 
features, based on severity of the symptoms (Sillence et al., 
1979). Patients with mild, non-deforming OI were classified 
as type I. Patients with moderate variable OI were indicated as 
type IV.  Patients with severe progressive deforming OI were 
designated as type III. Individuals with signs of calcification of 
interosseous membranes were enrolled as type V.
Clinical data was registered based on medical documentation. 
Genealogical data was recorded from the patients’ spoken Abbreviations: DI, dentinogenesis imperfecta; OI, osteogenesis imperfecta.
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words. Blood samples were obtained (for DNA analysis) from 
all available affected family members and their close healthy 
relatives.
Phenotype description was assessed by clinical observation. 
Skeletal fractures and deformations (severity, location) and 
extra-skeletal OI features (sclera color, DI) were noted. All sclera 
shades on the blue-gray scale were defined as “blue.” Phenotypic 
data was provided by the medical records, patients, and their 
relatives, including birth data (weight, height, intrauterine 
and birth fractures, preterm pregnancy); anthropometric data 
(weight and height); fracture history (time and location of the 
first fracture, total number of fractures, number of fractures 
per year); patient physical mobility; occurrence of hearing loss; 
and joint laxity. In order to exclude bias, the registration of the 
phenotype and the OI type classification were performed by a 
single medical professional. Fracture per year and total fracture 
values are presented to make data comparable with previous 
studies. Data regarding additional OI symptoms and features, 
including pulmonary function, cardiovascular system, BMD was 
incomplete and incomparable thus excluded from analysis in 
current study.
Genealogical data included OI history in the family, 
consanguinity data, and miscarriages. Pedigree trees were 
constructed for every kindred with the “Kinship2” package of the 
R statistical program v3.3.2. (R team, Austria).
The Shapiro–Wilk’s test was used to check normality of 
continuous variables. Normally distributed continuous data was 
presented as mean and the standard deviation (SD), continuous 
data lacking normal distribution is presented as median and 
range. The Student’s t-test was used to compare normally 
distributed continuous data, and Mann–Whitney U test was used 
to compare data without normal distribution.
The categorical data was expressed as percentages. The 
significance of associations between the genotype and phenotype 
manifestations was tested with Fisher’s χ2-test for categorical 
variables. P-values less than 0.05 were considered to be statistically 
significant. All statistical analyses were performed using R v3.3.2. 
software (R Team, Austria) (Chen et al., 2012).
Mutational Analysis of the COL1A1/2 
Genes
Genomic DNA purification was done with 3 ml of an EDTA-
preserved whole blood sample, using the Gentra Puregene Blood 
Kit (Qiagen, Germany) in accordance with the manufacturer’s 
protocol and stored at −80°C. gDNA samples were amplified 
with PCR using a 25 specially designed primer pairs covering 
the 5’ and 3’ untranslated region and 51 exons of the COL1A1 
gene; 36 primer pairs covering the 5’ UTR and 3’ UTR regions 
and 52 exons of the COL1A2 gene. The PCR reaction was 
performed in a total volume of 20 μl, which included 4 μl of 5× 
HOT FIREPol® Blend.
Master Mix Ready to Load with 7.5 mM MgCl2 (Solis 
BioDyne, Estonia), 1 μl each of forward and reverse primer 
(5 pmol), and 1 μl of gDNA (50 ng). PCR reaction was performed 
with a Thermal Cycler (Applied Biosystems, USA) PCR machine. 
The PCR touchdown program has been previously described 
(Ho Duy et al., 2016; Zhytnik et al., 2017). PCR products were 
electrophoresed through a 1.5% agarose gel, to control the 
quality of fragments. The PCR products then purified with 
exonuclease I and shrimp alkaline phosphatase (Thermo Fisher 
Scientific, USA). Sanger sequencing reactions were performed 
on the purified PCR fragments using a BigDye® Terminator v3.1 
Cycle Sequencing Kit (Applied Biosystems, USA). Reactions 
were processed on the ABI3730xl instrument. Applied 
Biosystems’ Sequence Scanner v1.0 and Mutation Surveyor 
DNA Variant analysis software v5.0.1. (SoftGenetics, USA) 
were used to analyze sequence products. Sequence products 
were further aligned to the GenBank human reference genome 
sequences of COL1A1 (gDNA NG_007400.1, complementary 
(cDNA) NM_000088.3) and COL1A2 (gDNA NG_007405.1, 
cDNA NM_000089.3). Sequencing data is available from the 
authors upon reasonable request. This study focused on the non-
synonymous and splice-site variants absent from the publicly 
available normal datasets (including dbSNP135 and the 1000 
Genomes Project) (Consortium T 1000 GP, 2015; Sherry et al., 
2001). PolyPhen-2, SIFT, and MutationTaster software tools were 
used to assess the pathogenic nature and functional impact of 
discovered variants (Kumar et al., 2009; Adzhubei et al., 2010; 
Schwarz et al., 2010). Variants not described in osteogenesis 
imperfecta variant database (http://www.le.ac.uk/ge/collagen/) 
were classified as novel (Dalgleish, 1997; Dalgleish, 1998; Ho 
Duy et al., 2016; Zhytnik et al., 2017). Mutational analysis of the 
patients with OI type V will be reported elsewhere.
All laboratory procedures and data analyses were performed 
at the University of Tartu, Estonia. The datasets used and analyzed 
during the current study are available from the corresponding 
author on reasonable request.
RESULTS
Clinical Characteristics of Ukrainian 
OI Population
A total number of 143 individuals from 94 unrelated OI families 
(66 males and 77 females) were included in the study. Within this 
cohort, there were no cases of consanguineous families. Out of 
93 families with known family history, 36 families had a previous 
history of OI. For one subject, there was no parent information, 
as he had grown up in an orphanage. Patients were classified in 
accordance with the new Sillence classification, as follows: type 
I, n = 67 (46.85%); type III, n = 24 (16.78%); type IV, n = 49 
(34.27%); and type V, n = 3 (2.10%). In the current study, there 
were no cases of OI type II (Figure 1A).
The age range of the patients was from 2 months to 65 years, 
with a mean age of 19.5 ± 14.4 years. Slightly more than half of 
the study subjects (n = 77, 54.23%) were in the “child” age group 
(i.e. between 0 and 17 years). A detailed description of the skeletal 
and nonskeletal clinical characteristics of the Ukrainian patient 
cohort is present in Table 1.
The median/(range) of total number of fractures per patient 
was 10.00 (0–300) (type I 5.00 [0–30], type III 20.00 [1–300], 
type IV 11.00 [0–60], and type V [median ± SD] 12.67 ± 11.72) 
(Figures 1B and 2). The number of fractures per year per patient 
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was 1.32 ± 2.88 (type I 0.50 ± 0.43, type III 3.51 ± 6.18, type IV 
0.83 ± 1.76, and type V 0.77 ± 0.23) (Figure 1C). The highest 
number of fractures in an individual patient (n = 300) occurred 
in a 35-year old patient with OI type III. Nine patients suffered 
intrauterine fractures (type III 30.43%, n = 7; type IV 4.17%, n = 
2). 19 patients suffered their first fracture during delivery (type I 
8.96%, n = 6; type III 26.09%, n = 6; type IV 12.50%, n = 6; type V 
33.33%, n = 1). The ages of first fracture for study participants was 
between 0 and 1 years for 22.70% of patients (n = 32); between 1 
and 2 years for 24.82% (n = 35); between 3 and 6 years for 17.02% 
(n = 24); and at ≥7years for 10.64% (n = 15). Seven patients 
(4.96%) did not experience fractures; of these, one was 50 years 
old (type I) and one was 33 years old (type IV). However, based 
on extraskeletal features, skeletal deformations, and positive OI 
history in the family, both these individuals were diagnosed with 
OI. The most commonly fractured bones were tubular bones: 
lower limbs (53.73%, n = 72); upper limbs (22.39%, n = 30); and 
both lower and upper limbs (17.16%, n = 23).
Deformities were present in the majority of the affected study 
participants (87.23%, n = 123). Type I patients mostly had either 
no deformities or mild deformities. The majority (81.56%, n = 
115) of subjects had deformities of the lower limbs of varying 
severity: severe n = 21 (type III, n = 16; type IV, n = 4; type 
V, n = 1); moderate n = 47 (type I, n = 12; type III, n = 7; type 
IV, n = 27, type V, n = 1); and mild (type I, n = 33, type IV, n = 
14). Spine deformations (scoliosis and kyphosis) were present 
in 77.30% (n = 109) of patients. More than half of the patients 
suffered from deformations of the upper limbs (65.96%, n = 
93). Approximately one third of patients had chest deformities 
(34.75%, n = 49). Most patients (74.29%, n = 104) were able to 
walk independently; 12.86% (n = 18) were able to walk with a 
support; and 12.14% (n = 17) used a wheelchair. Two patients 
were immobile (type III).
DI was observed in 54.68% (n = 76) of the subjects (type I, 
41.79%; type III, 70.83%; type IV, 61.22%; type V, 33.33%). Joint 
laxity was present in 26.62% (n = 37) of patients (type I, 24.24%; 
type III, 27.27%; type IV, 26.53%; type V, 66.67%). Two patients 
(types I and III) had contractures. The majority of the studied 
individuals (124 individuals, 87.32%) had blue eye sclera (type I, 
85.07%; type 3, 86.96%; type 4, 89.80%; and type V, 100%).
Hearing loss was noted in 22.38% of patients (n = 32). Of 
these, 22.38% were type I (n = 15), 20.83% were type III (n = 5), 
22.45% were type IV (n = 11), and 33.33% were type IV (n = 1). 
Congenital hearing loss was diagnosed in three patients (types I, 
III, and IV). Early hearing loss (at between 1 and 10 years) was 
noted in 12 patients. Nine patients had lost hearing between the 
ages of 11–20 years. Eight patients experienced hearing loss from 
maturity (aged over 20 years).
Spectrum of COL1A1/2 Pathogenic 
Variants in the Ukrainian OI Population
The mutational analysis highlighted that 60 (63.83%) of the 94 
Ukrainian OI families harbored pathogenic COL1A1/2 variants 
(Figure 3A). The number of patients harboring COL1A1/2 
pathogenic variants by OI type was as follows: type I, 23 (63.89%); 
type III, 14 (60.87%); type IV, 23 (69.70%). The number of 
pathogenic variants was 63, as three patients harbored double 
pathogenic variants (UA08, UA85 in both COL1A1/2; UA55 in 
COL1A1). A list of all observed variants is given in Table 2.
The number of COL1A1 pathogenic variants was 48/63 
(76.19%), whereas in the COL1A2 gene, 15/63 (23.81%) variants 
were observed (Figure 3B). All pathogenic variants were in 
a heterozygous state, underlying the dominant inheritance 
pattern of the disorder in this cohort. Novel pathogenic variants 
were represented by 27 (42.85%) variants (20 in COL1A1; 7 
in COL1A2) absent from the osteogenesis imperfecta variant 
database (Table 2).
Structural variants comprised slightly more than half of 
revealed pathogenic variants (31/63, or 49.21%), whereas 
haploinsufficiency variants were observed in 32/63 (50.79%) of 
cases (Figure 4A).
Of the 31 structural pathogenic variants, 18 (58.06%) were 
situated in the COL1A1 gene and 13 (41.94%) in the COL1A2 
gene. Glycine substitution was present in 24 (77.42%) of the 
missense variants, of which 14 (58.33%) and 10 (41.67%) 
were in the COL1A1 and COL1A2 genes, respectively. Glycine 
substitution with serine was present in 11 (45.83%) Gly missense 
variants, seven in the COL1A1, and four in the COL1A2 genes 
(Figures 4B–D). Two individuals harbored missense non-Gly 
FIGURE 1 | (A) Distribution of osteogenesis imperfecta (OI) types in Ukrainian OI study cohort. (B) Total number of fractures in Ukrainian OI study cohort by OI type. 
(C) Number of fractures in Ukrainian OI study cohort per year by OI type.
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substitution pathogenic variants in the C-terminal propeptide of 
the collagen α1 chain: UA21 c.3655G > GT (p.[Asp1219Tyr]) and 
UA71 c.4356G > GC (p.[Gln1452His]).
Thirty (93.75%) of the haploinsufficiency variants arose in 
the COL1A1 gene and 2 (6.25%) in the COL1A2. Frameshift 
pathogenic variants were represented by 12 (37.50%) variants, 
11 (91.67%) in the COL1A1 gene, and one (8.33%) in the 
COL1A2. Furthermore, 11 (34.38%) splice site variants were 
discovered (nine of COL1A1; one of COL1A2), as well as 10 
(31.25%) nonsense variants, all of which altered the COL1A1 
gene (Figures 4B–D).
Correlation Between Clinical 
Characteristics and Genotypes 
of Ukrainian OI Patients
The results of the analyses show a clear correlation between OI 
type and collagen defect. Haploinsufficiency collagen pathogenic 
variants correlate with milder OI types (p = 0.007). Interestingly, 
haploinsufficiency pathogenic variants in the COL1A2 gene both 
caused severe OI, whereas the COL1A1 variants caused moderate 
and mild OI (p = 0.003). However, there was no difference in 
OI types between structural COL1A1 and COL1A2 pathogenic 
variants (p = 0.895) (Table 3).
TABLE 1 | Clinical characteristics of the study cohort of Ukrainian osteogenesis imperfecta (OI) patients divided by clinical OI type. 
OI type I OI type III OI type IV OI type V All OI types
Individuals 67 (46.85%) 24 (16.78%) 49 (34.27%) 3 (2.10%) 143 (100%)
Families with OI history (n = 93) 19 (52.78%) 2 (8.70%) 14 (42.42%) 1 (50%) 36 (38.71%)
Gender male/female 35/32 4/20 25/24 2/1 66/77
Age, years (mean ± SD, range) (n = 142) 20.3 ± 15.9
(2–65y)
16.3 ± 11.0
(2m–35y)
20.0 ± 13.9
(6m–50y)
17.7 ± 15.2
(4–34y)
19.5 ± 14.4
(2m–65y)
Children (0–17y)
 0–5y
 6–10y
 10–17y
37 (55.22%)
17 (25.37%)
8 (11.94%)
12 (17.91%)
13 (54.17%)
4 (16.67%)
5 (20.83%)
4 (16.67%)
25 (51.02%)
8 (16.33%)
8 (16.33%)
9 (18.37%)
2 (66.67%)
1 (33.33%)
0 (0.00%)
1 (33.33%)
77 (54.23%)
30 (20.98%)
21 (14.69%)
26 (18.18%)
Total fracture number (n = 142)
(median [range]/mean ± SD)
5.00/(0–30) 20.00/(1–300) 11.00/(0–60) 12.67 ± 11.72 10.00/(0–300)
Fractures per year (n = 142) (median [range]/mean ± SD) 0.41 (0–2) 1.63 (0.14–30) 0.83 (0–10) 0.77 ± 0.23 0.61 (0–30)
Time of the first fracture (n = 141)
 No fractures
 Intrauterine
 During delivery
 ≤1y
 1–2y
 3–6y
 ≥7y
6 (8.96%)
0 (0.00%)
6 (8.96%)
11 (16.42%)
19 (28.36%)
14 (20.90%)
11 (16.42%)
0 (0.00%)
7 (30.43%)
6 (26.09%)
6 (26.09%)
1 (4.35%)
3 (13.04%)
0 (0.00%)
1 (2.08%)
2 (4.17%)
6 (12.50%)
14 (29.17%)
14 (29.17%)
7 (14.58%)
4 (8.33%)
0 (0.00%)
0 (0.00%)
1 (33.33%)
1 (33.33%)
1 (33.33%)
0 (0.00%)
0 (0.00%)
7 (4.96%)
9 (6.38%)
19 (13.48%)
32 (22.70%)
35 (24.82%)
24 (17.02%)
15 (10.64%)
Most fractured body compartment (n = 134)
 All tubular bones
 Lower limb
 Upper limb
 Phalanx
 Spine
 Ribs
9 (14.75%)
25 (40.98%)
20 (32.79%)
6 (9.84%)
1 (1.64%)
0 (0.00%)
3 (13.04%)
18 (78.26%)
2 (8.70%)
0 (0.00%)
0 (0.00%)
0 (0.00%)
11 (23.40%)
27 (57.45%)
7 (14.89%)
0 (0.00%)
0 (0.00%)
2 (4.26%)
0 (0.00%)
2 (66.67%)
1 (33.33%)
0 (0.00%)
0 (0.00%)
0 (0.00%)
23 (17.16%)
72 (53.73%)
30 (22.39%)
6 (4.48%)
1 (0.75%)
2 (1.49%)
Deformations (n = 141)
 Upper limb
 Lower limb
 Spine
 Chest
32 (47.76%)
45 (67.16%)
40 (59.70%)
6 (8.96%)
21 (91.30%)
23 (100.00%)
23 (100.00%)
22 (95.65%)
38 (79.17%)
45 (93.75%)
44 (91.67%)
19 (39.58%)
2 (66.67%)
2 (66.67%)
2 (66.67%)
2 (66.67%)
93 (65.96%)
115 (81.56%)
109 (77.30%)
49 (34.75%)
Mobility (n = 140)
 Immobile
 Wheelchair
 Walking with support
 Walking independently
0 (0.00%)
0 (0.00%)
2 (2.99%)
66 (98.51%)
1 (4.35%)
13 (56.52%)
9 (39.13%)
0 (0.00%)
0 (0.00%)
4 (8.51%)
7 (14.89%)
36 (76.60%)
1 (33.33%)
0 (0.00%)
0 (0.00%)
2 (66.67%)
2 (1.43%)
17 (12.14%)
18 (12.86%)
104(74.29%)
DI (yes) (n = 139) 28 (41.79%) 17 (70.83%) 30 (61.22%) 1 (33.33%) 76 (54.68%)
Blue sclera (yes) 57 (85.07%) 20 (86.96%) 44 (89.80%) 3 (100%) 124(87.32%)
Hearing loss (yes) 15 (22.38%) 5 (20.83%) 11 (22.45%) 1 (33.33%) 32 (22.38%)
Time of hearing loss start (n = 32)
at birth
 1–10y
 11–20y
 21–30y
 31–40y
1 (6.67%)
5 (33.33%)
5 (33.33%)
3 (20.00%)
1 (6.67%)
1 (20.00%)
2 (40.00%)
2 (40.00%)
0 (0.00%)
0 (0.00%)
1 (9.09%)
5 (45.45%)
1 (9.09%)
4 (36.36%)
0 (0.00%)
0 (0.00%)
0 (0.00%)
1 (100.00%)
0 (0.00%)
0 (0.00%)
3 (9.38%)
12 (37.50%)
9 (28.13%)
7 (21.88%)
1 (3.13%)
Data are n (%) unless otherwise indicated. SD is standard deviation.
COL1A1/2 Pathogenic Variants in Ukrainian OIZhytnik et al.
6 August 2019 | Volume 10 | Article 722Frontiers in Genetics | www.frontiersin.org
FIGURE 2 | Total number of fractures in Ukrainian OI patient by OI type and age.
FIGURE 3 | (A) Percentages of the families of Ukrainian OI study cohort with and without COL1A1/2 pathogenic variants (n = 94). (B) Distribution of pathogenic 
variants in Ukrainian OI study cohort between the COL1A1 and COL1A2 genes (n = 63).
COL1A1/2 Pathogenic Variants in Ukrainian OIZhytnik et al.
7 August 2019 | Volume 10 | Article 722Frontiers in Genetics | www.frontiersin.org
TABLE 2 | The COL1A1 (gDNA NG_007400.1, cDNA NM_000088.3) and COL1A2 (gDNA NG_007405.1, cDNA NM_000089.3) mutational spectrum among studied 
Ukrainian OI families. 
# Patient ID Gene Pathogenic variant Exon Pathogenic 
variant type
Protein alteration Protein structural 
domain
OI type
 1. COL1A1 pathogenic variants
 a. Haploinnsufficiency COL1A1 pathogenic variants
1 UA48† COL1A1 c.1675_delG‡ 25 Frameshift p.Ala559Profs*21 Helical I
2 UA91 COL1A1 c.1816_del G‡ 26 Frameshift p.Ala606Leufs*160 Helical I
3 UA95† COL1A1 c.3489_del G‡ 48 Frameshift p.Pro1165Leufs*74 Helical IV
4 UA72† COL1A1 c.3759_delG‡ 50 Frameshift p.Asp1254Thrfs*77 C-terminal propeptide I
5 UA15† COL1A1 c.459_delT 5 Frameshift p.Gly154Alafs*111 N-terminal propeptide I
6 UA14† COL1A1 c.579_delT 7 Frameshift p.Gly194Valfs*71 Chain I
7 UA61 COL1A1 c.2393_dupC‡ 35 Frameshift p.Gly800Argfs*5 Helical I
8 UA67 COL1A1 c.2523_delT 37 Frameshift p.Gly842Alafs*266 Helical I
9 UA31 COL1A1 c.2821_delG‡ 40 Frameshift p.Gly941Valfs*167 Helical IV
10 UA44† COL1A1 c.1789G > T 26 Nonsense  p.Glu597* Helical I
11 UA50 COL1A1 c.3076C > T 43 Nonsense p.Arg1026* Helical I
12 UA19 COL1A1 c.658C > T 9 Nonsense p.Arg220* Helical I
13 UA45† COL1A1 c.1081C > T 17 Nonsense p.Arg361* Helical IV
14 UA64 COL1A1 c.1243C > T 19 Nonsense p.Arg415* Helical I
15 UA17† COL1A1 c.1426G > T‡ 21 Nonsense p.Arg476* Helical I
16 UA93 COL1A1 c.2179C > T‡ 32 Nonsense p.Gln727* Helical IV
17 UA73† COL1A1 c.3807G > A 49 Nonsense p.Trp1269* C-terminal propeptide I
18 UA22† COL1A1 c.495T > A‡ 6 Nonsense p.Tyr165* Helical I
19 UA25 COL1A1 c.904-9G > A 13i Splice site – – I
20 UA38 COL1A1 c.2613+6T > C 38i Splice site – – IV
21 UA40† COL1A1 c.1614+1G > A 23i Splice site – – IV
22 UA41† COL1A1 c.3815−1G > A‡ 48i Splice site – – IV
23 UA43† COL1A1 c.858+1G > A 12i Splice site – – IV
24 UA56† COL1A1 c.858+1G > A 12i Splice site – – IV
25 UA80 COL1A1 c.804+1G > A 11i Splice site – – IV
 b. Structural COL1A1 pathogenic variants
26 UA101 COL1A1 c.3226G > A 45 Missense  p.Gly1076Ser Helical IV
27 UA23 COL1A1 c.769G > A 11 Missense  p.Gly257Arg Helical I
28 UA27† COL1A1 c.2101G > T 31 Missense  p.Gly701Cys Helical III
29 UA62 COL1A1 c.1057G > T 17 Missense p.Gly353Cys Helical IV
30 UA39 COL1A1 c.3652G > A 49 Missense p.Ala1218Thr Helical IV
31 UA57† COL1A1 c.757C > T 11 Nonsense p.Arg253* Helical IV
32 UA21† COL1A1 c.3655G > T‡ 49 Missense p.Asp1219Tyr C-terminal propeptide IV
33 UA71† COL1A1 c.4356G > C‡ 52 Missense p.Gln1452His C-terminal propeptide III
34 UA89† COL1A1 c.653G > A 9 Missense p.Gly218Asp Helical I
35 UA53† COL1A1 c.734G > A‡ 10 Missense p.Gly245Glu Helical I
36 UA33† COL1A1 c.742G > A 10 Missense p.Gly284Arg Helical III
37 UA30† COL1A1 c.1319G > C‡ 20 Missense p.Gly440Ala Helical III
38 UA76† COL1A1 c.1192G > A‡ 18 Missense p.Gly398Ser Helical III
39 UA94† COL1A1 c.1588G > A 23 Missense p.Gly530Ser Helical III
40 UA10 COL1A1 c.2362G > A 35 Missense p.Gly788Ser Helical IV
41 UA78 COL1A1 c.2434G > A‡ 36 Missense p.Gly812Ser Helical IV
42 UA05† COL1A1 c.2461G > A 37 Missense p.Gly821Ser Helical III
43 UA96 COL1A1 c.2560G > A 38 Missense p.Gly854Ser Helical I
44 UA32 COL1A1 c.1A > C‡ 1 Missense p.Met1Leu Signal peptide I
 2. COL1A2 pathogenic variants 
 a. Haploinsufficiency COL1A2 pathogenic variants
45 UA82 COL1A2 2093_2110_dup‡ 35 Frameshift p.Leu699_Leu704dup Helical III
46 UA92† COL1A2 c.2026-1_2042_dup‡ 33i-34 Splice site – – III
 b. Structural COL1A2 pathogenic variants
47 UA86† COL1A2 c.2045G > T‡ 34 Missense  p.Gly682Val Helical III
48 UA37 COL1A2 c.2233G > C 37 Missense  p.Gly745Arg Helical III
49 UA83† COL1A2 c.2027G > A 34 Missense p.Gly676Asp Helical IV
50 UA51† COL1A2 c.3034G > A 46 Missense p.Gly1012Ser Helical III
51 UA54† COL1A2 c.982G > A 19 Missense p.Gly328Ser Helical III
52 UA65 COL1A2 c.1009G > A 19 Missense p.Gly337Ser Helical IV
53 UA102† COL1A2 c.2224G > A‡ 37 Missense p.Gly742Arg Helical I
54 UA74 COL1A2 c.2288G > T 37 Missense p.Gly763Val Helical III
55 UA47 COL1A2 c.2314G > A 38 Missense p.Gly772Ser Helical IV
(Continued)
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Type of pathogenic variant appeared to be crucially important 
for total fracture number, as well as for number of fractures per 
year. Patients with structural OI pathogenic variants had more 
fractures than did patients with haploinsufficiency defect. For 
those patients with structural defect (Gly substitutions), patients 
with COL1A1 pathogenic variants had more total fractures than 
did COL1A2 patients (p = 0.0247) (Table 3).
There were clear correlations between skeletal deformations 
and collagen defect. Patients with a structural collagen defect 
suffered from more severe skeletal deformations than did patients 
with a haploinsufficiency OI defect (p = 0.001; p = 5.80e-05; p = 
2.37e-05; p = 2.0e-04) (Table 3). Interestingly, patients with 
structural OI type I revealed more severe deformations in the 
lower limbs and spine, compared to those with haploinsufficiency 
OI type I (p = 0.022, p = 0.029). Gly substitutions in COL1A2 
genes led to more severe cases of chest and spine deformations, 
compared to Gly substitutions in the COL1A1 gene (p = 0.010, 
p = 0.004). Patients with structural pathogenic variants were less 
mobile than patients with haploinsufficiency pathogenic variants 
(p = 0.023). Also those with structural COL1A2 pathogenic 
TABLE 2 | Continued
# Patient ID Gene Pathogenic variant Exon Pathogenic 
variant type
Protein alteration Protein structural 
domain
OI type
56 UA69† COL1A2 c.2324G > A 38 Missense p.Gly775Glu Helical IV
57 UA90† COL1A2 c.1220T > C‡ 22 Missense p.Leu407Pro Helical I
 3. Double pathogenic variants in the COL1A1 and COL1A2
58 UA55† COL1A1 c.2195_delA‡ 32 Frameshift p.Glu732Aspfs*34 Helical IV
COL1A1 c.2548_2549_dupC‡ 36 Frameshift p.Gly851Luefs*258 Helical 
59 UA85 COL1A1 c.370-1G > A 4i Splice site - - I
COL1A2 c.2642A > C‡ 41 Missense p.Glu881Ala Helical 
60 UA08† COL1A1 c.334-1G > A‡ 3i Splice site - - IV
COL1A2 c.2642A > C‡ 41 Missense p.Glu881Ala Helical 
Patients with sporadic pathogenic variants are marked with an obelisk (†). Novel pathogenic variants unreported in the collagen type I variant database (http://www.le.ac.uk/ge/
collagen/) are marked with a diesis (‡).
FIGURE 4 | (A) Percentages of the structural and haploinsufficiency COL1A1/2 pathogenic variants in Ukrainian OI study cohort. (B) Mutational spectrum of the 
COL1A1/2 genes in Ukrainian OI study cohort. (C) Types of pathogenic variants in the COL1A1 gene in Ukrainian OI study cohort. (D) Types of pathogenic variants 
in the COL1A2 gene in Ukrainian OI study cohort.
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variants were less mobile than patients with structural COL1A1 
pathogenic variants (p = 0.038).
There was no correlation between pathogenic variant type 
and presence of DI or hearing loss in the cohort of Ukrainian 
patients. However, the correlation of blue sclera with the presence 
of collagen I pathogenic variants (p = 0.011) was notable, as the 
majority of non-collagenous OI cases had white eye sclera.
DISCUSSION
Phenotype Characteristics of Ukrainian 
OI Cohort
In current study, the clinical and molecular characteristics 
of individuals from 94 osteogenesis imperfecta families from 
Ukraine were presented. Of the 143 subjects, 46.85% were 
diagnosed with OI type I. 16.78% of the patients had OI 
type III and 34.27% were described as having type IV. Three 
patients were classified as OI type V due to enlargement of the 
hyperplasic callus and were guided toward further analysis of 
the IFITM5 gene, which will be presented elsewhere (Table 1, 
and Figure 1A). Previous studies showed that, amongst Polish 
OI patients (n = 123), patients with OI types I, III, and IV 
comprised 44%, 33%, and 21% of the cohort, respectively 
(Rusinska et al., 2017). In a Russian pediatric study (including 
data from 31 regions of the Russian Federation), patients (n = 
117) were classified as follows: OI type I, 59%; type III, 27%; and 
type IV, 14% (Yakhyayeva et al., 2016).
Interestingly, the current study revealed a low percentage 
of patients with OI type III. However, this may be connected 
with the difficulty involved for patients with severe forms of OI 
forms to travel to the study venue. Nevertheless, OI patients 
with milder OI types are usually rarer in population cross-
sectional studies compared with nationwide register-based 
studies, due to poor diagnostics and less patient interest. The 
current study illustrates the effective work of the Ukrainian 
Association of Crystal People, which enabled the involvement in 
research of those individuals with milder OI. In studies of other 
populations, the distribution by types (I/III/IV) were as follows: 
Vietnamese 31.5%/31.5%/37%, Taiwanese 58%/7%/35%, Chinese 
28%/38%/34%, Israeli 61%/21%/14%, Swedish 68%/13%/19%, 
Norwegian 77%/9%/11%, and Finnish 72%/4%/20% (Hartikka 
et al., 2004; Lin et al., 2015; Lindahl et al., 2015; Binh et al., 
2017). There may be various reasons for the observed contrasts 
in the proportion of OI types across different populations, such 
as sample sizes, diagnostics, and classification. Additionally, 
methods of patient recruitment might affect distribution of OI 
types in our cohort, as patients were enrolled via OI patients’ 
organization and thus OI individuals with more severe OI forms 
might be overrepresented in contrast to individuals with mild 
TABLE 3 | Relationships between clinical characteristics and collagen I pathogenic variant types for cohort of Ukrainian OI patients. 
Structural 
OI type I/
haploin­
sufficiency OI 
type I
All structural/
all haploin­
sufficiency
Haploin­
sufficiency 
COL1A1/
haploin­
sufficiency 
COL1A2
Structural 
COL1A1/
structural 
COL1A2
Gly COL1A1/
Gly COL1A2
Gly > Ser 
COL1A1/
Gly > Ser 
COL1A2
Collagen OI/
non­collagen 
OI
All OI patients
 Type I
 Type III
 Type IV
7/16
–
–
–
29/31
7/16
12/2
10/13
27/2
15/0
0/2
12/0
18/11
5/2
7/5
6/4
20/10
8/1
6/5
6/4
7/4
1/0
3/2
3/2
60/34
23/13
14/9
23/10
p-value – 0.003* 0.004* 0.895 0.271 1 0.317
Blue sclera 5/15 24/30 26/2 15/9 16/8 4/3 54/23
p-value 0.481 0.329 1 1 1 1 0.011*
Mobility
 Wheelchair
 Walking with support
 Walking independently
 Immobile
–
1/1
5/15
–
8/2
7/5
12/23
–
1/1
5/0
21/0
–
2/6
6/1
9/3
–
1/6
7/1
11/2
–
1/1
3/1
2/2
–
10/5
12/4
35/22
0/1
p-value 0.481 0.023* 0.169 0.038* 0.002* 1 0.465
Deformation severity 
(p-values)
 Upper limb
 Lower limb
 Spine
 Chest
0.065
0.022*
0.029*
1
0.001*
5.803e-05*
2.37e-05*
2.0e-04*
0.734
0.048*
0.285
0.598
0.162
0.765
0.224
0.190
0.051
0.138
0.010*
0.004*
0.714
0.2
0.543
0.2
0.558
0.473
0.441
0.125
Total fracture number 
(median [range]/mean ± SD)
6.00/4.00
(4–14)/(0–25)
28.00/6.00
(4–300)/(0–40)
6.00/13.00
(0–40)/(6–20)
10.00/30.00
(4–300)/(7–50)
7.00/30.00/
(2–49)/(7–50)
8.00/12.50
(4–49)/(7–30)
10/6.5
(0–300)/(0–50)
p-value 0.1184 0.001* 0.4899 0.3131 0.0247* 0.5918 0.046*
Fracture number per year 
(median [range]/
mean ± SD)
1.00/0.73
(0.4–1.17)
(0–2)
1.52/0.83
(0.4–8.57)/
(0–30)
0.8/15.37
(0–2.69)/
(0.74–30)
1.63/1.39
(0.4–8.57)/
(0.7–3.08)
1.33/1.52
(0.25–7.5)/
(0.77–3.08)
1.48/0.69
(1–3.75)/
(0.78–1.75)
1.18/0.54
(0–30)/(0–5.56)
p-value 0.483 0.001* 0.282 0.651 0.538 0.352 0.004*
Statistically significant p-values are marked with *. Data are n, unless otherwise indicated. SD is standard deviation.
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OI forms. Being a spectrum of disorders, OI type classification 
remains subjective, as some of the individuals might develop 
border phenotypes and thus might be classified by different 
health professionals differently. Current circumstances might 
add bias and contrast to results of different studies. However, the 
influence of genetic factors cannot be excluded.
In the current study, the number of fractures per year was 
strongly aligned with those of a previous Swedish OI study 
(type I 0.57 ± 0.68; type III 3.83 ± 9.32; and type IV1.33 ± 1.38) 
(Lindahl et al., 2015). In contrast to Swedish register-based 
study, clinical features in our cohort were partially self-reported 
and it might bias the data. However, similar to previous studies, 
more deformed and fractured body compartments occurred in 
the lower limbs, which may be due to the greater loading of the 
lower limbs (Binh et al., 2017). We discovered two adult patients 
without history of fractures, but with other OI symptoms and OI 
history in the family. Both cases lacked pathogenic variants in 
COL1A1/2 genes. Therefore, it would be particularly interesting 
to identify causative pathogenic variants in these cases and 
further investigate reasons of fracture absence.
The proportion of patients suffering from DI (55%) was higher 
than in Swedish (25%) and Brazilian (27%) OI cohorts, but similar 
to the proportions in Taiwanese (44%) and Vietnamese (61%) OI 
populations (Lin et al., 2015; Lindahl et al., 2015; Binh et al., 2017; 
Brizola et al., 2017). The percentage of patients with blue sclera 
(87%) aligns with the proportions observed in previous studies 
(e.g. 82%, 93%, 90%, and 80% of patients in Swedish, Brazilian, 
Taiwanese, and Vietnamese cohorts, respectively) (Lin et al., 
2015; Lindahl et al., 2015; Binh et al., 2017; Brizola et al., 2017).
Genotype Characteristics of Ukrainian 
OI Cohort
According to previous studies, collagen I pathogenic variants 
account for between 60 and 90% of OI cases (Dalgleish, 1998). 
In a recent major genetic study of 598 OI individuals from 
487 families of Caucasian, Hispanic, Arab, and Asian origin, 
the proportion of collagen pathogenic variants was 86% 
(Bardai et al., 2016). However, in population-based OI studies, 
COL1A1/2 percentages vary. In this current study, the proportion 
of COL1A1/2 pathogenic variants in Ukrainian OI patients 
comprised 63.83%, which appears to be lower than in Northern 
Europe [e.g. in Estonian and Swedish (87%) and Finnish (91%) 
populations] (Hartikka et al., 2004; Lindahl et al., 2015; Zhytnik 
et al., 2017). At the same time, these results show that Ukrainian 
OI patients harbor a higher number of COL1A1/2 pathogenic 
variants than do patients from Russia and Asian populations. 
Amongst patients from Russia (Yakutia and Bashkortostan 
regions), the percentage of collagen I pathogenic variants was 
41% (Khusainova et al., 2012). Asian populations from Vietnam, 
Taiwan, and Korea were characterized by COL1A1/2 pathogenic 
variants of 59%, 51%, and 52%, respectively (Lee et al., 2006; Lin 
et al., 2015; Ho Duy et al., 2016).
We have previously analyzed Estonian OI patients, using same 
analysis methods and laboratory techniques (Zhytnik et al., 2017). 
Regarding the fact, that proportion of the COL1A1/2 mutations 
in the Estonian OI cohort composed ~90%, we suppose that 
analysis methods and techniques could not influence proportion 
of the collagen I mutations in the Ukrainian OI cohort.
Panel sequencing of the autosomal recessive OI genes in 
Ukrainian OI patients without collagen I mutations is ongoing 
and will be reported elsewhere. Patients with contractures will 
be scanned for presence of variants in the PLOD2 and FKBP10 
genes to specify presence of a Bruck syndrome diagnosis.
The current analysis also illustrated that the proportion of 
pathogenic variants of the COL1A2 gene was less than that of 
the COL1A1 (23.81% and 76.19%, respectively). Similar results 
were observed in Estonian, Swedish, Finnish, and Taiwanese 
populations (Hartikka et al., 2004; Lin et al., 2015; Lindahl et al., 
2015; Zhytnik et al., 2017). However, in a Russian study of 83 OI 
patients of Turkic and Slavic origin, and in a study of 11 Egyptian 
patients, pathogenic COL1A2 variants were not observed 
(Khusainova et al., 2012; Aglan et al., 2015).
Another interesting result of the current study was that the 
amounts of structural and haploinsufficiency variants were 
almost equal (49.21% and 50.79%, respectively). This was similar 
to results reported for a Swedish OI cohort (Lindahl et al., 2015). 
In contrast, in Estonian and Finnish cohorts, the proportions of 
structural OI pathogenic variants were significantly lower (31% 
and 30%, respectively), whereas in Taiwanese and Vietnamese 
cohorts, the proportion was higher (78%) (Lin et al., 2015; Ho 
Duy et al., 2016; Zhytnik et al., 2017).
The reasons for differences in genotypes may be similar to 
those for differences in OI type distributions: i.e. sample sizes, 
methods of patient recruitment, and potential variations in OI 
genetic epidemiology between different populations.
As expected, the majority of haploinsufficiency variants caused 
OI types I and IV. Only two individuals with haploinsufficiency 
variants had OI type III (Table 2). Investigation of genotypes 
in patients with OI type III and COL1A2 haploinsufficiency 
variants for presence of mutations in other OI genes is essential 
and current patients are included into panel sequencing cohort. 
The majority of patients with structural pathogenic variants were 
represented by individuals with OI types IV and III. However, 
seven individuals had OI type I, of which five harbored glycine 
substitutions. Patients with double pathogenic variants had 
moderate and mild phenotypes IV and I. Patient UA08 had 
blue sclera, hearing loss (started at the age of 10). Patients UA55 
and UA85 had blue sclera, DI, but no hearing loss. It is known 
that phenotype severity depends not only on the type of the 
pathogenic variant, but also on helical location and substituted 
residue, which contribute to the development of the phenotype 
(Marini et al., 2007; Rauch et al., 2010). It could be proposed, that 
patient UA55 who had two frameshift variants in the COL1A1 
gene might have had a haploinsufficiency of the collagen α1 chain 
and suffer from quantitative collagen defect.
Unexpectedly mild phenotypes were harbored by patients 
UA89, UA53, UA96, UA23, UA102. All of these patients suffered 
OI I, however had Gly structural substitutions, which generally 
are associated with severe OI. Interestingly, COL1A1 c.769G > 
A (p.[Gly257Arg] variant (UA23) was reported for 37 times, 
causing all range of classical non-lethal OI types I, III, IV. Number 
of observations might have underlined phenotype diversity 
evidence, stating broader spectrum of affection compared to 
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variants with lack of data. Another COL1A1 variant c.653G > 
A (p.[Gly218Asp]) (UA89) was also described in a patient with 
OI IV. Whereas variant c.2560G > A was previously found in a 
patients with OI I/IV (Marini et al., 2007). Both patients had 
apparently mild types and differences in phenotype presentation 
might be connected to classification bias of border OI forms 
(i.e. type I/IV). Moreover, phenotypes of OI patients might be 
affected by the treatment, and real effect of the mutation might 
remain unresolved.
The above discussion indicates that, although the general 
effect of collagen I pathogenic variants on phenotype is 
understood, current knowledge does not reflect all of the 
nuances of genotype-phenotype correlations. OI is known to 
show incomplete penetrance, thus the clinical presentation can 
vary to a great degree even between same family members (Van 
Dijk and Sillence, 2014). Recent studies show over hundred loci 
in the human genome influencing bone mineral density (Estrada 
et al., 2012; Rivadeneira and Mäkitie, 2016). In addition bone 
morphology and quality, bone strength, and toughness, also 
influence fracture risk (Chesnut and Rosen, 2001; Rivadeneira 
and Mäkitie, 2016). Bone is influenced by metabolic (glucose, 
lipids, calcium, hormones), biomechanical (muscle strain, body 
weight, and composition), material (collagen, mineralization), 
cellular (osteoclast, osteoblast, osteocyte activity, and 
differentiating), growth, and remodeling factors (Rivadeneira 
and Mäkitie, 2016). All these factors can potentially influence 
the phenotypic expression of collagen gene mutations by yet 
undescribed molecular pathways. Further investigations of the 
clinical manifestations and molecular characteristics of patients 
may contribute to the understanding of OI phenotypes’ diversity.
In current study we present 27 novel OI pathogenic variants, 
harbored by Ukrainian OI patients. Some novel pathogenic 
variants alter previously-reported positions with new 
substitutions; this could be of particular interest to the exploration 
of the OI phenotypical spectrum and its interconnections 
with genotypes. Moreover, current pathogenic variants enrich 
database of OI pathogenic variants and have practical use for OI 
genetic diagnostics. The percentage of novel pathogenic variants 
in Ukrainian OI cohort was 42.85%. Despite the numerous 
reported variants, there are still many novel collagen type I 
pathogenic variants, each of which improves the understanding 
of OI genotype-phenotype correlations.
As it is known, splice site mutations might result in exon 
skipping, intronic inclusion, or activation of cryptic splice sites 
(Marini et al., 2007). Changes in mRNA and protein depend on 
whether these alterations are in frame or produce translational 
frameshifts. Pathogenic mechanism of the identified novel OI 
haploinsufficiency variants is yet to be investigated with further 
functional studies. In general, haploinsufficiency mutations 
result in a severely truncated mRNA molecules, which cause 
activation of pretermination stop codon, followed by mediated 
mRNA decay (Chang et al., 2007; Fang et al., 2013; Symoens 
et al., 2014).
Structural pathogenic variants cause synthesis of an abnormal 
protein. Defective protein is secreted into the extracellular 
matrix and interferes with fibrillogenesis, collagen-matrix, bone 
cells, and hydroxyapatite. The structural pathogenic variants 
affect extracellular matrix more severely than haploinsufficiency 
variants (Bodian et al., 2008; Marini et al., 2017). Although exact 
mechanism of the structural pathogenic mutations has to be 
further elucidated with functional studies, according to in silico 
analysis and description of functional domains in the collagen 
type I protein, following consequences of the novel structural 
variants can be predicted: COL1A1, c.3655G > T, p.(Asp1219Tyr), 
UA21, OI IV
Substitution in identical position was described previously 
by Lindahl et al. c.3655G > A (p.[Asp1219Asn]) (Lindahl et al., 
2011). However, in contrast to Ukrainian patient, Swedish 
patient had mild OI phenotype. It can be partly explained by the 
hydrophobic side chain of the Tyr, which compared to uncharged 
side chain of Asn, has larger effect on procollagen properties.
Both variants alter C-cleavage site, what causes severe 
processing defect, alteration of the C-propeptide cleavage, and 
increased mineralization (Lindahl et al., 2011; Marini et al., 
2017). However, we do not have bone mineral density data of the 
UA21 patient to confirm high bone mass phenotype.
COL1A1, c.4356G > C, p.(Gln1452His), UA71, OI III
Current structural variant also alters C-cleavage site of the 
procollagen, what is critical for mineralization. In addition, 
according to in silico analysis, current variant causes gain of 
donor splice site and might result in a cryptic splice site. Current 
mutation might be particularly interesting for further functional 
investigation, as patient suffered more than 300 fractures during 
lifetime and developed hearing loss at the age of 2.
COL1A1, c.734G > A, p.(Gly245Glu), UA53, OI I
According to collagen type I functional domains, current 
variant might affect keratan sulfate proteoglycans binding region, 
α2β1 integrin, and interleukin 2 (IL2) binding sites (Sweeney 
et al., 2008). In this way, variant might alter protein function.
COL1A1, c.1319G > C, p.(Gly440Ala), UA30, OI III
Variant affects keratane sulfate proteoglycans binding domain 
and probably creates a new donor splice site (Sweeney et al., 
2008).
COL1A1, c.1192G > A, p.(Gly398Ser), UA76, OI III
Variant is located in the proposed site of discoidin domain 
receptor 2 (DDR2) binding site, von Willebrand Factor 
binding site, and dermatan/chondroitin sulfate proteoglycans/
decorin binding region (Sweeney et al., 2008). Marini et al. has 
described patient with OI III/IV harboring variant c.1192G > T 
(p.[Gly398Cys]) (Marini et al., 2007). More severe phenotypes 
of UA76 patient might be caused by more distant properties of 
Ser compared to Cys in relation to Gly and have greater effect on 
protein function.
COL1A1, c.2434G > A, p.(Gly812Ser), UA78, OI IV
Current variant is located in the major ligand binding region 
(MLBR) 2, proposed region for lethal OI mutations (Marini 
et al., 2007). Variant overlaps with α2β1 integrin binding site and 
glycation region (Sweeney et al., 2008).
COL1A1, c.1A > C, p.(Met1Leu), UA32, OI I
The variant alters initiating methionine, causing activation of 
potential downstream translation initiation site with new reading 
frame. Substitutions of the Met in the COL1A1 were previously 
described and resulted in OII.
COL1A2, c.2045G > T, p.(Gly682Val), UA86, OI III
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Variant is located in the MLBR2 and interrupts cartilage 
oligomeric matrix protein and phosphophoryn, secreted protein, 
acidic, and rich in cysteine (SPARC) binding sites, keratan sulfate 
proteoglycans binding region (Sweeney et al., 2008).
COL1A2, c.2224G > A, p.(Gly742Arg), UA102, OI I
Variant is located in the MLBR2, overlaps with SPARC binding 
site, cell interaction domain, cartilage oligomeric matrix protein, 
phosphoryn binding sites (Sweeney et al., 2008).
COL1A2, c.1220T > C, p.(Leu407Pro), UA90, OI I
Variant is located in the dermatan/chondroitin sulfate 
proteoglycans/decorin binding region.
COL1A2, c.2642A > C, p.(Glu881Ala), UA85, OI IV, and 
UA08, OI I
Variant is located at the delineate clusters of lethal OI mutations 
on the α2(I) chain. Current variant might alter proposed site 
of dermatan/chondroitin sulfate proteoglycans/decorin, IL2, 
amyloid precursor protein binding regions (Sweeney et al., 
2008). Both variants are harbored by individuals with additional 
COL1A1 variants.
Genotypes were assessed with Sanger sequencing, which is 
considered to be a powerful and accurate method of mutational 
analysis. Special design of primers allowed the capture of all 
inter-exon junction regions and 5’UTR, 3’UTR regions. However, 
potential limitations include the inability of Sanger sequencing 
to detect whole gene or exon deletions and duplications. The 
number of COL1A1/2 pathogenic variants may therefore be 
underestimated. Differences in sample sizes may also contribute 
to the variation of results between studies.
Genotype­Phenotype Analysis
OI genotype-phenotype correlations have been a subject of 
interest for many decades. Although the association of pathogenic 
variant with OI phenotype remains elusive, previous studies 
showed COL1A1 pathogenic variants to be associated with more 
severe phenotypes than were COL1A2 (Marini et al., 2007; Mrosk 
et al., 2018). In the current study, a higher fracture number was 
observed in structural COL1A1 cases; among COL1A2 cases there 
were more cases with severe deformations of the spine and chest.
These results show the presence of a strong correlation 
between collagen type I defect and severity of OI, which aligns 
well with previous studies. Haploinsufficiency collagen I defects 
cause milder, less fragile, and less deformed OI types (Marini 
et al., 2007; Amor et al., 2011; Lindahl et al., 2015). Although 
in a Swedish OI cohort, the difference between type I patients 
with structural and haploinsufficiency collagen defects were 
insignificant, in the current study, structural type I patients had 
more deformed lower limbs and more fractures. This underlies 
the vital importance of a normal collagen helical structure (rather 
than amount).
In contrast to previous studies, the current study did not find 
an association between DI and pathogenic variant type. This 
apparent lack of correlation may be attributed to the presence of 
the additional non-OI etiology of dental issues in the Ukrainian 
cohort (Lin et al., 2009; Amor et al., 2011; Lindahl et al., 2015).
Although there are numerous different genes associated 
with OI, the differences in phenotypes between collagen and 
non-collagen OI cases were insignificant, except that of blue 
sclera (which was also associated with collagen I pathogenic 
variants in previous studies) (Lindahl et al., 2015). The overlap 
of OI phenotypes with different genotypes remains a focus for 
future research.
The current study’s results corroborate the absence of a 
correlation between collagen pathogenic variants and hearing 
loss. No previous studies have detected factors, which could 
explain hearing loss in OI families, and this remains a vital topic 
for future research. Number of pediatric patients with hearing 
loss in Ukrainian OI cohort was high, so it would be especially 
interesting to identify non-collagen OI genes in remained 
patients (Hartikka et al., 2004; Amor et al., 2011).
CONCLUSIONS
The current paper presents the phenotype and genotype 
characteristics of 94 Ukrainian OI families for the first time. 
These patients exhibited OI phenotypes I (46.85%), III (16.78%), 
IV (34.27%), and V (2.10%). COL1A1/2 pathogenic variants 
were identified in 63.83% of the 94 screened unrelated patients, 
which were equally divided between structural (49.21%) and 
haploinsufficiency (50.79%) pathogenic variants. 27 novel OI 
causing pathogenic variants in the COL1A1/2 genes were presented 
in this study. Genotype-phenotype analysis supported previous 
findings on the dependence of OI phenotype severity on type of 
defect. Future research will focus on the performance of a whole 
exome sequencing analysis of patients negative for COL1A1/2 
pathogenic variants, in order to identify OI genetic causes.
There appears to be very little data available on OI patients 
from East Slavic populations. The results of this current 
research will enrich the OI variant database and contribute 
to the understanding of genotype-phenotype correlations in 
osteogenesis imperfecta. The results of this research may also be 
used to promote further research, treatment, and diagnostics of 
OI in Ukraine, which will result in the improvement of patients’ 
quality of life and accessibility to treatment.
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